Indofarma Tbk. vs Kian Santang Muliatama Tbk. — how do they compare? Indofarma Tbk. trades at Rp126 (market cap 390.51B), while Kian Santang Muliatama Tbk. trades at Rp114 (market cap 163.43B, 36.43M 24h volume). The key difference: Indofarma Tbk. is far larger — about 2.4× Kian Santang Muliatama Tbk.'s market cap. Which is the better fit depends on your goals.
| INAF | RGAS | |
|---|---|---|
Market Cap | 390.51B | 163.43B |
Volume | — | 36.43M |
Lot | — | 364.26K |
Turnover | — | 4B |
Average Price | — | 109.89 |
Value | — | 4B |
Indicative Equilibrium Price | — | 114 |
Indicative Equilibrium Volume | — | 5.9K |
Trailing returns across standard periods
Latest headlines on both assets
PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.
Read more on INAF →PT Kian Santang Muliatama Tbk (the Entity) was established based on the Notarial Deed of Artisa Khamelia Ramadiyanti, S.H., M.Kn., No. 634, dated November 28, 2018. The Entity started its commercial operations on 2019. The controlling party for the Company is Edy Nurhamid Amin.
Read more on RGAS →